Purpose: Topoisomerase I inhibitors have shown promising anti leukemic activity in acute myelogenous leukemia (AML) and myelodysplastic syndrome. In this phase I study, we investigated the toxicity profile, pharmacokinetics, and activity of a prolonged continuous infusion schedule of the colloidal dispersion formulation of 9-amino-camptothecin (9-AC/CD) in patients with acute leukemia.
Introduction
Camptothecin and its analogues are anti-cancer drugs that bind to the nuclear enzyme topoisomerase I (topo I). They are able to stabilize the complexes formed by topo I and DNA [1] . Stabilization results in DNA single strand breaks, which are converted into double strand breaks after collision with the replication fork, resulting in G2-phase cell-cycle arrest and cell death [1] [2] [3] [4] . This cytotoxic activity is supported by the lactone form of the terminal ring (E ring) which is common to different analogues. 9-Amino-camptothecin (9-AC) is a semi synthetic analogue of camptothecin obtained by substitutions at C9 position [5] . 9-AC is a weak substrate for the P-glycoprotein membrane pump [6] . In mice human tumor xenograft models, 9-AC induced long-lasting remissions of tumors including colon, breast, ovary and lung cancer [1, 6, 7] In these systems, the use of prolonged schedules of administration, either continuous intravenous infusions or repeated subcutaneous injections, leads to improved antitumor efficacy and tolerance [1, [7] [8] [9] . Such improvement of the 9-AC therapeutic index may be related to the achievement of sustained levels of the lactone form for prolonged periods of time [1, 9] .
The dose-limiting toxicity of 9-AC in phase I studies in solid tumors was myelosuppression [10] [11] [12] , supporting the rationale for investigations in acute leukemia. In addition, we have shown that 9-AC is an effective antileukemic agent in a severe immunodeficient mouse (SCID) model of human acute myelogenous leukemia (AML) [13] .
We designed a phase I study testing a seven-day continuous infusion schedule of the new formulation of 9-AC (9-AC colloidal dispersion 9-AC/CD) in patients with acute leukemia. The objectives of this study were to establish the maximal tolerated dose (MTD) and toxicity of 9-AC/CD, to determine the pharmacokinetic and pharmacodynamic profiles, and to evaluate the antileukemic activity of the drug.
Patients and methods

Study group
Patients with refractory AML and acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia in blastic phase (CML-BP) were entered on study after informed consent was obtained according to institutional guidelines. Refractory acute leukemia was defined as (1) lack of an objective response (complete or partial) following induction therapy; (2) first relapse occurring after a first complete remission (CR) lasting less than 12 months; or (3) second relapse or beyond. Other eligibility criteria included age greater than 15 years; performance status 2 or better (Zubrod scale); adequate renal (creatinine < 1.5 mg/dl) and hepatic functions (bilirubin <1.5 mg/dl); and no chemotherapy for at least two weeks.
Pretreatment evaluation included a history and physical examination; complete blood cell count, differential and platelet count; serum chemistries; bone marrow aspirate, biopsy, chemical and enzymatic stains and cytogenetic studies. Diagnosis was confirmed by cytological and histochemistry criteria according to the French-American-British classification [14] . Follow-up studies included CBC, differential and platelet counts three times weekly until CR, then at least once weekly; serum chemistries at least weekly; and bone marrow aspiration on days 14 and 21 after the start of therapy and then every three to seven days until CR.
Treatment schedule
9-AC/CD (NSC 603071) was supplied by the Division of Cancer Treatment, NCI, in vials that contained 1 mg or 2 mg of 9-AC, with dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol and mannitol. A special diluent that contained 20% dextrose, 0.9% sodium chloride, and sterile water was used to reconstitute 9-AC/CD. Ten milliliters of special diluent was added to the 1 mg/vial product or 20 ml to the 2 mg/vial product, such as the resulting mixture contained 100 ul/ml of 9-AC/CD. The appropriate dose of the reconstituted 9-AC/CD was then transferred into a 50 or 100 ml medication cassette reservoir (Pharmacia Deltec, Inc, St. Paul, MN). An additional amount of special diluent was used to obtain the volume necessary to administer the dose. 9-AC/CD was infused through a central venous access device using CADD-1 pumps (Pharmacia Deltec, Inc.) without any in-line filters.
The drug was administered as a 24-hour continuous intravenous infusion over seven days every three to four weeks. The starting dose was 0.2 mg/m 2 /d for seven days (i.e., 1.4 mg/m 2 per course). This dose was 50% of the MTD identified in phase I solid tumor studies using a three-day continuous infusion [12] . It was selected because longer exposure schedules of topo I inhibitors are associated with more significant toxicities (e.g., mucositis with topotecan). Subsequent dose escalations were in 50% increments until grade 1 toxicity (other than nausea and myelosuppression) was observed, then in 30% to 35% increments until the MTD was reached. Cohorts of three patients were entered on each dose level, and additional patients could be entered according to usual '3 + 3' design [16] .
During neutropenia, all patient received oral prophylactic antibiotic therapy with antibacterial agents (trimethoprim-sulfamethoxazole 1 tablet twice daily, ciprofloxacin 500 to 750 mg twice daily, or levofloxin 500 mg daily), anti-fungal agents (fluconazole 100 to 200 mg daily), and anti-viral agents (acyclovir 200 mg twice daily or valocyclovir 500 mg daily). During and up to two days after chemotherapy, patients received antiemetic prophylaxis. Thereafter, occasional nausea was managed at the discretion of the attending physician. Diarrhea was managed conservatively according to its severity with either loperamide or opiates administered orally. When fever (3* 101 °F) requiring intravenous antibacterial antibiotics persisted for longer than 48 to 72 hours without positive identification of organisms, intravenous liposomal amphotericin B was added.
The MTD was defined as one dose level below the one that produced, in at least two of a maximum of six patients receiving their first course of treatment, either (1) grade 3 or greater non hematologic toxicity based on the National Cancer Institute grading system [17] ; or (2) severe hematologic toxicity defined as persistent pancytopenia with less than 5% cellular bone marrow without evidence of residual leukemia lasting for six weeks or more from the start of the course.
Patients who had neither antileukemic effect nor grade 2 or greater toxicity during the first course received a second course at one dose level escalation. Patients manifesting antileukemic effect received a second course at the same level if toxicity was grade 2, and at 20% to 25% dose reduction if toxicity was grade 3. If patients achieved remission, they were planned to receive two courses of consolidation therapy with 9-AC/CD at the same dose level that induced remission if it was below the MTD, or at 20% to 25% dose reduction from the MTD.
Response and toxicity criteria
A complete remission (CR) was defined as normalization of blood and bone marrow, with 5% or less blasts in a normocellular or hypercellular bone marrow, a granulocyte count above 10 3 /ul, and a platelet count above 100 x 10 3 /ul. Patients who met these criteria but still had 6% to 25% marrow blasts were considered to have a partial remission (PR). Hematologic improvement (HI) was defined as a CR but without recovery of the platelets above 100 x 10 3 /ul. Other responses were considered as failures, and categorized as (1) early death, if death occurred within two weeks from the start of therapy; (2) aplastic death, if death occurred without evidence of hematologic recovery and with less than 20% marrow leukemic infiltrate (MLI = % [blasts + promyelocytes] x marrow cellularity); (3) secondary resistance, if the MLI was reduced below 20% but increased later; (4) primary resistance, if the MLI did not decrease below 20% [18] . Toxicity was graded on a scale of 0 to 5 using the National Cancer Institute criteria [17] . All patients who received at least one dose of 9-AC/CD were considered evaluable for toxicity.
Historical control patients and analysis of outcome
In order to assess the impact of giving 9-AC/CD as a phase I single agent on outcome of patients with AML, we compared the results of 9-AC/CD to matched historical patients treated with 'standard'AML salvage regimens. These regimens were those containing high-dose cytosine arabinoside (ara-C, HDAC), i.e., ara-C equal or greater than 1 g/m 2 per dose, generally combined with other drugs. To ensure balance of major prognostic factors between the two groups, patients were matched on a one-to-three basis within the prognostic groups described by Estey et al. [19] This stratification system of refractory or relapsed AML recognizes four groups on the basis of (1) duration of first CR, (2) number of salvage attempt, and (3) response to previous salvage attempt. Survival was calculated using the method of KaplanMeier, and comparison was made using the log-rank test.
Pharmacokinetic studies
Blood samples were collected at the following time points: pre-dose, 5, 15, 30 and 45 minutes, 1,1.5, 2,4,6,12, 24,48,72,120,144,168,170,172 and 176 hours after start of 9-AC/CD infusion. Plasma samples were immediately subjected to a solid phase extraction procedure using the method published by Takimoto et al. [20] with minor modification. Briefly, 9-AC/CD lactone (9-AC/CD-L) was isolated by solid phase Abbreviations: AML -acute myelogenous leukemia; AUL -acute undifferentiated leukemia; ALL -acute lymphoblastic leukemia; CML-BP -chronic myelogenous leukemia in blastic phase; AHDantecedent hematologic disorder.
extraction using Accubond C18, Ice x 100 mg SPE column (J&W Scientific, Folsom, CA). Eluent was placed into cryovials and frozen at -70 °C until analysis. Liquid chromatographic separation was achieved by gradient elution on a Magellen C8, 250 x 4.6 mm, 5 um particle size packing, analytical column (Phenomenex, Torrance, CA). Mobile phase consisted of mixture of 0.1% (v/v) triethylamine (pH = 2.5 with trifluoroacetic acid) and acetonitrile. Initial conditions consisted of 75% of 0.1% (v/v) triethylamine and 25% acetonitrile. The amount of triethylamine was decreased to 60% and the acetonitrile increased to 40% over 10 minutes in a linear fashion and then returned to initial conditions over an additional 10 minutes. Column effluent was monitored using fluorometric detector (Waters 470 Scanning Fluorescence Detector, Waters Corp., Milford, MA) at wavelengths of 375 nm for excitation and 470 nm for emission. Retention time for 9-AC/CD-L was 5.4 minutes. No plasma components were observed at the retention time of 9-AC/CD. The method is suitable for routine analysis of 9-AC/CD-L in human plasma at concentration range from 0.25 to 20 nM. The intra-and inter-day coefficient of variance was less than 15%. All reagents and chemicals used were HPLC-graded (Fisher Scientific, Fair Lawn, NJ). The samples were quantified by using peak area ratio of the sample peak over the internal standard. All samples were analyzed and data collected using Millennium Work Station (Waters Corp., Milford, MA).
9-AC/CD lactone clearance and systemic exposure (AUQ was determined by fitting a two-compartmental model utilizing maximum a posteriori probability (MAP) estimator. The population parameter and variance estimates used came from published data [11] . All pharmacokinetic modeling was completed using ADAPT II V.4.0 (USC, Los Angeles, CA) [21] .
Results
The characteristics of the 39 patients in the study are shown in Table 1 . Their median age was 56 years (range 30-74); and performance status was 0 or 1 in 29 patients (74%). Thirty-six patients had AML. 9-AC/CD was given as second salvage or more to 24 of these including 5 who had never achieved remission, and 1 who had relapsed after allogeneic bone marrow transplantation. Twelve patients with AML received 9-AC/CD as their first salvage attempt: 10 after a first CR lasting less than six months, 1 with primary refractory disease, and 1 had a first CR longer than two years. All patients with AML had previously received intermediate or high-dose ara-C as part of induction/consolidation or salvage therapy. Two patients with ALL were given 9-AC/CD as a second salvage attempt for refractory disease, and one patient with refractory CML-BP received 9-AC/CD as a fourth salvage attempt.
Toxicity
Two patients could not be evaluated for toxicity. One patient at level 0.75 mg/m 2 /d x 7 had insufficient followup, and one patient at level 1.6 mg/m 2 /d x 7 had persistent grade 2 mucositis at the start of 9-AC/CD. Major toxicity was mucositis which occurred in 16 patients usually between day 7 and day 14 after the start of 9-AC/ CD (median 9 days). It involved posterior orophayngeal mucosa (pharynx) rather than anterior (tongue, cheeks) and lasted three to four days. In all cases, cultures for HSV were negative. MTD was reached at 1.6 mg/m 2 /d x 7 with three of six patients having dose limiting grade 4 mucositis. Since only grade 1 toxicity had been observed No other severe non hematologic toxicities were observed. Mild nausea and vomiting were seen in 3 of 10 patients at level 1.4 mg/m 2 /d x 7. Elevation of bilirubin levels above 2 mg% was observed in 3 patients and creatinine levels above 2 mg% in 2 patients. In all instances, increase of bilirubin and/or creatinine occurred during febrile episodes. Twenty-five patients had thirtythree febrile episodes. These included 10 episodes of fever of unknown origin; 11 pneumonias including 3 fungal pneumonia; 9 documented infections; 8 sepsis episodes; and 1 CMV infection. All patients had bone marrow or peripheral blood leukemic involvement before day 32 of treatment, and prolonged myelosuppression induced by 9-AC/CD was not observed.
Eight patients received a second course of 9-AC/CD that was begun at a median of 18 days (range 15-51 days) after the start of course 1 and one patient received 12 courses. All but one received only one additional course of 9-AC/CD because of leukemia progression (increased dose in six patients, decreased in one patient and identical in one patient). One patient had stable disease and could receive 11 additional courses.
Response
Thirty-seven patients were evaluable for response (Table 4) . No complete or partial responses were observed. Seventeen patients (46%) had a decrease of MLI below 20%, including four patients who achieved a transient disappearance of marrow blasts with marrow cellularity < 10%. Three of these four patients received 9-AC/CD at 1.4 or 1.6 mg/m 2 /d x 7.
Pharmacokinetic studies
Pharmacokinetic analysis of 9-AC/CD lactone was performed in 11 patients (Table 5) . Data fitted with a two-compartment model using bayesian estimates (see The limited number of patients tested and inter-patient variability may explain the lack of correlation. The overall results also indicate a relatively high AUC, short terminal half-life, and Css of approximately 10 nmol/1. As previously observed [10] , there was a trend for increased 9-AC lactone clearance with increased doses.
There was no difference in Css and AUC values between patients with toxicity (mucositis, diarrhea) or MLI < 20% and patients without these toxicities. Since all patients recovered with leukemia, the use of hematologic parameters for pharmacodynamic analysis was not valid.
Outcome and comparison with historical controls
Absence of response to 9-AC/CD raises questions about the use of phase I single agents in these patients, particularly with regards to its impact on patient outcome as compared with standard salvage regimens. Therefore, we compared the outcome of the 36 patients with AML (the largest and most homogeneous group among study patients) to 108 matched historical controls treated with 'standard' AML salvage regimens at MD. Anderson Abbreviations: Tl/2 -elimination half-life of 9-AC lactone; AUC -area under the concentration-vewui-time curve; Clp -normalized plasma clearance of 9-AC lactone; Css -steady-state concentration of 9-AC lactone; Vss -volume of distribution of 9-AC lactone at steady-state in the central compartment. was higher in the 9-AC/CD group {P = 0.02), while more patients in this group had performance status of 2 or worse (P -0.036) as shown in Table 6 . Survival was not different between the two groups ( Figure 3 ; log-rank P-value 0.19).
Discussion
Results achieved with the topoisomerase I inhibitor topotecan have shown CR rates of 2% to 11% in patients with heavily pretreated AML while a CR rate of 30% was seen in patients with relatively chemptherapy-naive myelodysplastic syndromes [22] [23] [24] [25] . These results have spurred interest in other topoisomerase I inhibitors. In this phase I study, we evaluated a seven-day continuous infusion of 9-AC/CD in patients with refractory or relapsed acute leukemia. The MTD was 1.4 mg/m 2 /d for seven days, i.e., 9.8 mg/m 2 per course. The dose limiting toxicity was mucositis; other side effects, such as diarrhea or nausea and vomiting, were unusual. No objective responses were observed by accepted response criteria. However, 9-AC/CD showed anti-leukemic activity, with 46% of patients in this heavily pretreated study group experiencing a decrease in MLI to below 20%.
The rationale for the use of the colloidal dispersion formulation of 9-AC is based on the practical improvements of the drug administration. Preclinical studies did not show significant differences in pharmacokinetic or toxicity profiles between 9-AC/CD and the previous formulation in dimethylacetamide (data on file, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD). In a phase I study conducted in patients with solid tumors, Siu et al. [15] showed myelosuppression to be the doselimiting toxicity of 9-AC/CD, and confirmed the absence of toxicities specific to the colloidal dispersion formulation.
Similar to the results reported with topotecan [24, 25] , the MTD of 9-AC in patients with acute leukemia was three to four fold higher than the MTD in patients with solid tumors with a 72-hour continuous infusion of 9-AC/DMA [11, 12] . This significant dose escalation was achieved despite the more prolonged infusion schedule (seven-day versus three-day continuous infusion). In preclinical studies, prolonged schedules led to increased steady-state concentrations of the circulating lactone form of 9-AC, which was associated with myelosuppression in clinical studies [10, 12, 15] . In the present study, we could not demonstrate a correlation between the dose of 9-AC/CD and steady-state concentrations of 9-AC lactone form. However, as in the study of Siu et al. [15] , steady-state concentration was close to 10 nmol/1, the level shown to be the threshold for antitumor activity in animal studies [9] . In addition, probably because of the prolonged infusion schedule, the AUC in our study was on average four to six times higher than in previous studies of 9-AC [10, 15] . Taken together, our toxicity and pharmacokinetic data suggest that a prolonged infusion of 9-AC/CD results in protracted exposure to optimal lactone concentrations. Since significant dose escalation as compared to shorter schedules was possible, the therapeutic index might have been improved by this schedule.
No objective responses were observed in this study. However, the characteristics of the study group (see Table 6 ) may have accounted for the poor results. Comparison with matched historical controls who received 'standard' salvage treatments in our center showed that the response rate was reduced (0% versus 8%). However, reflecting decreased toxicity, there were less deaths among 9-AC/CD treated patients, and ultimately survival was not different. This comparison indicates that despite producing less CR than standard treatment, the use of phase I single agents do not result in reduced survival and should be offered as first salvage therapy for refractory/relapsed AML.
In summary, this phase I study showed that the MTD of 9-AC/CD given, as a seven-day continuous infusion was 1.4 mg/m 2 /d in patients treated for acute leukemia. Further investigations of the prolonged infusion schedule of 9-AC/CD alone or in combination with other active anti-leukemic agents (i.e., cytarabine or topo II inhibitors) are warranted to establish the activity of 9-AC/CD in patients with less advanced stages of acute leukemia or myelodysplastic syndrome.
